To cite this paper use one of the standards below:
For the treatment of HIV-TB co-infection, many drugs are used concomitantly for a long time, which decrease patient compliance. Therefore, it is necessary to develop new compounds with multi-target characteristics, which can treat HIV-TB with greater effectiveness and less toxicity. Therefore, the objective of this work was the synthesis of new analogues of etravirine, used in anti-HIV therapy, containing in their structure isoniazid and pyrazinamide, applied in TB treatment. These molecules were designed via molecular hybridization tool between the DAPY skeleton, the main pharmacophoric fragment of etravirine, the 1,2,3-triazole ring and isatin nucleus. Until now, ten products were synthesized, four intermediates and six new final products, with a high degree of purity and in moderate yields. The final compounds are being evaluated as to the inhibitory activity on a TRHXB2 RNA-dependent DNA polymerase (RDDP), using recombinant purified HIV-1 enzyme, and antimycobacterial activity in drugs susceptible and resistant M. tuberculosis.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper